Sirio Pharma Co., Ltd.

Shenzhen Stock Exchange 300791.SZ

Sirio Pharma Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 336.64 M

Sirio Pharma Co., Ltd. Shareholders' Equity is USD 336.64 M for the year ending December 31, 2023, a -14.01% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Sirio Pharma Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 391.48 M, a -2.25% change year over year.
Sirio Pharma Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 400.50 M, a 19.77% change year over year.
Sirio Pharma Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 334.39 M, a 19.72% change year over year.
Sirio Pharma Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 279.31 M, a 145.00% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shenzhen Stock Exchange: 300791.SZ

Sirio Pharma Co., Ltd.

CEO	Mr. Peiqing Li
IPO Date	Sept. 25, 2019
Location	China
Headquarters	No.83 Taishan Road
Employees	2,610
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Consumer Packaged Goods Cosmetics Personal Care Pet Food Pharmaceuticals Plastics Soft Drinks & Sodas

Description

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplements to customers worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; various nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.

Key trends

Past 5 years